DE60133271D1 - Behandlung von knorpelerkrankungen - Google Patents

Behandlung von knorpelerkrankungen

Info

Publication number
DE60133271D1
DE60133271D1 DE60133271T DE60133271T DE60133271D1 DE 60133271 D1 DE60133271 D1 DE 60133271D1 DE 60133271 T DE60133271 T DE 60133271T DE 60133271 T DE60133271 T DE 60133271T DE 60133271 D1 DE60133271 D1 DE 60133271D1
Authority
DE
Germany
Prior art keywords
igf
treatment
cartilage
cordial
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60133271T
Other languages
English (en)
Other versions
DE60133271T2 (de
Inventor
Yves Dubaquie
Ellen H Filvaroff
Henry B Lowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE60133271D1 publication Critical patent/DE60133271D1/de
Application granted granted Critical
Publication of DE60133271T2 publication Critical patent/DE60133271T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE60133271T 2000-05-16 2001-05-16 Behandlung von knorpelerkrankungen Expired - Lifetime DE60133271T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20449000P 2000-05-16 2000-05-16
US204490P 2000-05-16
US24898500P 2000-11-15 2000-11-15
US248985P 2000-11-15
PCT/US2001/015904 WO2001087323A2 (en) 2000-05-16 2001-05-16 Method for treating cartilage disorders

Publications (2)

Publication Number Publication Date
DE60133271D1 true DE60133271D1 (de) 2008-04-30
DE60133271T2 DE60133271T2 (de) 2009-04-23

Family

ID=26899527

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60133271T Expired - Lifetime DE60133271T2 (de) 2000-05-16 2001-05-16 Behandlung von knorpelerkrankungen

Country Status (9)

Country Link
US (4) US20030069177A1 (de)
EP (1) EP1282437B1 (de)
AT (1) ATE389416T1 (de)
AU (1) AU2001263215A1 (de)
DE (1) DE60133271T2 (de)
DK (1) DK1282437T3 (de)
ES (1) ES2301547T3 (de)
HK (1) HK1050321A1 (de)
WO (1) WO2001087323A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1099443A1 (de) 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplantations/Implantatsvorrichtung und ihre Herstellungsmethode
US7387889B2 (en) * 2002-08-22 2008-06-17 Massachusetts Institute Of Technology Measurement of concentrations and binding energetics
AU2004216551B2 (en) * 2003-02-26 2008-09-18 Zimmer Orthobiologics, Inc. Preparation for repairing cartilage tissue, especially articular cartilage defects
EP1740190A1 (de) * 2004-03-05 2007-01-10 Synthes GmbH Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelersatz in vitro
WO2005122723A2 (en) * 2004-06-09 2005-12-29 Beth Israel Deaconess Medical Center Compositions and methods that enhance articular cartilage repair
EP1764117A1 (de) 2005-09-20 2007-03-21 Zimmer GmbH Implantat zur Wiederherstellung von Knorpeldefekten und Verfahren zu seiner Herstellung
EP1989289B1 (de) 2006-02-07 2017-01-04 Spinalcyte, LLC Verfahren und zusammensetzungen zur wiederherstellung von knorpel mit einem in-vivo-bioreaktor
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
GEP20125659B (en) * 2006-12-29 2012-10-10 Ipsen Pharma Sas Pharmaceutical compositions containing glucagon-like peptide-1 (glp-1)
RU2011118341A (ru) 2008-10-06 2012-11-20 3-Д Матрикс, Лтд. (Jp) Агент для окклюзии тканей
KR101977846B1 (ko) 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
WO2013070880A1 (en) * 2011-11-09 2013-05-16 Spinalcyte, Llc Fibroblasts for treatment of degenerative disc disease
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
WO2014004467A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
EP2869903B1 (de) 2012-07-06 2018-11-28 3-D Matrix Ltd. Füllabschlussverfahren für peptidlösungen
EP3011015B1 (de) 2013-06-19 2021-02-24 Spinalcyte, LLC Fettgewebezellen für chondrozytenanwendungen
EP3116524B1 (de) 2014-03-10 2018-11-28 3-D Matrix Ltd. Peptides autoassémblants pour le traitement de la bulle pulmonaire
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
BR112016019510A2 (pt) 2014-03-10 2017-10-24 3 D Matrix Ltd esterilização e filtração de composições de peptídeos
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
CN117085140A (zh) 2017-12-15 2023-11-21 立美基股份有限公司 表面活性剂肽纳米结构及在药物递送中的用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4444047A (en) * 1979-06-29 1984-04-24 Vdo Adolf Schindling A.G. Apparatus for determining the fuel consumption of injection internal combustion engines
EP0023469B1 (de) 1979-07-16 1983-07-20 Ciba-Geigy Ag Nachbehandlung von mit Flammschutzmitteln veredelten, cellulosehaltigen Fasermaterialien mit flüssigem Ammoniak
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
WO1987001038A1 (en) 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
EP0308500B1 (de) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung
CA1314507C (en) 1987-04-23 1993-03-16 Edith Yee-Tak Wong Secretion of insulin-like growth factor-i in e. coli
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE116335T1 (de) 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DE68905203T2 (de) 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE500903C2 (sv) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Bergborrningsrigg
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
CA2114251C (en) 1991-08-01 2007-11-06 Peter Gluckman Igf-1 to improve the neural condition
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
ATE187889T1 (de) 1992-06-12 2000-01-15 Cephalon Inc Vorbeugung und behandlung der peripheren neuropathie
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
WO1994016722A1 (en) 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
JPH09500088A (ja) 1993-01-29 1997-01-07 アムジェン ボールダー インコーポレイテッド 創傷治癒用組成物
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
CA2179597A1 (en) 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
EP0736038B1 (de) 1993-12-23 2001-07-04 Novo Nordisk A/S Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5728676A (en) 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5596844A (en) * 1995-02-03 1997-01-28 Kalinowski; Juan R. Foldable portable building
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0828758B1 (de) 1995-05-26 2001-08-29 Theratechnologies Inc. Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz
NZ310778A (en) 1995-06-07 1999-10-28 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
JPH11508608A (ja) 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
EP0956041A1 (de) 1996-09-16 1999-11-17 Dalhousie University Verwendung von igf-1 zur behandlung von polyzystischer nierenkrankheit und damit verbundene indikationen
IL129772A0 (en) 1996-11-06 2000-02-29 Genentech Inc Constrained helical peptides and methods of making same
AU7891098A (en) 1996-12-27 1998-07-31 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
EP1067959A2 (de) * 1998-04-03 2001-01-17 Chiron Corporation Verwendung von igf1 zur behandlng von knorpelkrankheiten
AU767141B2 (en) 1998-10-02 2003-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
IL143834A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
JP2003518917A (ja) 1999-05-19 2003-06-17 ゼンコー 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質
CA2402780A1 (en) 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists

Also Published As

Publication number Publication date
ES2301547T3 (es) 2008-07-01
US20100130411A1 (en) 2010-05-27
ATE389416T1 (de) 2008-04-15
US20090011988A1 (en) 2009-01-08
EP1282437A2 (de) 2003-02-12
HK1050321A1 (en) 2003-06-20
US20030069177A1 (en) 2003-04-10
EP1282437B1 (de) 2008-03-19
WO2001087323A3 (en) 2002-04-11
AU2001263215A1 (en) 2001-11-26
DK1282437T3 (da) 2008-06-30
US20030211992A1 (en) 2003-11-13
US7947650B2 (en) 2011-05-24
DE60133271T2 (de) 2009-04-23
WO2001087323A2 (en) 2001-11-22
US8110548B2 (en) 2012-02-07
US7423017B2 (en) 2008-09-09

Similar Documents

Publication Publication Date Title
DE60133271D1 (de) Behandlung von knorpelerkrankungen
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
DE60041052D1 (de) Derivate der z-domäne des proteins a von staphylococcus (spa), welche mit mindestens einer domäne des humanen faktors viii interagieren
EP1408986A4 (de) Proteomimetische verbindungen und verfahren
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
ATE162532T1 (de) Merschliches cnp-gen und vorläufer protein
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE286974T1 (de) Therapeutische domänen des von willebrand-faktor
ATE439856T1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ES2072868T3 (es) Proteina capaz de unir la fibronectina y su preparacion.
DK0817851T3 (da) DNA, der koder for humant papillomvirus type 18
PT914419E (pt) Ratinhos transgenicos capazes de expressar o factor de inibicao de leucemia
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
DE69607034T2 (de) Pcna bindende substanz
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
WO2002012326A3 (en) Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
ATE148744T1 (de) Neue thrombininhibitorische proteine aus landblutegeln
ES2189213T3 (es) Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition